Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer

Author(s):  
David L. Hermanson ◽  
Laura Bendzick ◽  
Dan S. Kaufman
2015 ◽  
Vol 33 (1) ◽  
pp. 15-27 ◽  
Author(s):  
Justyna Mikuła-Pietrasik ◽  
Patrycja Sosińska ◽  
Eryk Naumowicz ◽  
Konstantin Maksin ◽  
Hanna Piotrowska ◽  
...  

Cytotherapy ◽  
2013 ◽  
Vol 15 (10) ◽  
pp. 1297-1306 ◽  
Author(s):  
Melissa A. Geller ◽  
David A. Knorr ◽  
David A. Hermanson ◽  
Lee Pribyl ◽  
Laura Bendzick ◽  
...  

2018 ◽  
Vol 29 ◽  
pp. ix24
Author(s):  
C.-P. Huang ◽  
S.-Y. Chen ◽  
H.-H. Lai ◽  
Y.-H. Lin ◽  
C.-T. Su ◽  
...  

2019 ◽  
Vol 21 (3) ◽  
Author(s):  
John S. Schardt ◽  
Madeleine Noonan-Shueh ◽  
Jinan M. Oubaid ◽  
Alex Eli Pottash ◽  
Sonya C. Williams ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Tamás Vancsik ◽  
Domokos Máthé ◽  
Ildikó Horváth ◽  
Anett Anna Várallyaly ◽  
Anett Benedek ◽  
...  

Modulated electro-hyperthermia (mEHT), induced by 13.56 MHz radiofrequency, has been demonstrated both in preclinical and clinical studies to efficiently induce tumor damage and complement other treatment modalities. Here, we used a mouse xenograft model of human melanoma (A2058) to test mEHT (~42°C) both alone and combined with NK-cell immunotherapy. A single 30 min shot of mEHT resulted in significant tumor damage due to induced stress, marked by high hsp70 expression followed by significant upregulation of cleaved/activated caspase-3 and p53. When mEHT was combined with either primary human NK cells or the IL-2 independent NK-92MI cell line injected subcutaneously, the accumulation of NK cells was observed at the mEHT pretreated melanoma nodules but not at the untreated controls. mEHT induced the upregulation of the chemoattractant CXCL11 and increased the expression of the matrix metalloproteinase MMP2 which could account for the NK-cell attraction into the treated melanoma. In conclusion, mEHT monotherapy of melanoma xenograft tumors induced irreversible heat and cell stress leading to caspase dependent apoptosis to be driven by p53. mEHT could support the intratumoral attraction of distantly injected NK-cells, contributed by CXCL11 and MMP2 upregulation, resulting in an additive tumor destruction and growth inhibition. Therefore, mEHT may offer itself as a good partner for immunotherapy.


Oncogenesis ◽  
2021 ◽  
Vol 10 (7) ◽  
Author(s):  
Suresh Chava ◽  
Suresh Bugide ◽  
Yvonne J. K. Edwards ◽  
Romi Gupta

ABSTRACTOvarian cancer is the leading cause of gynecological malignancy-related deaths. Current therapies for ovarian cancer do not provide meaningful and sustainable clinical benefits, highlighting the need for new therapies. We show that the histone H3K79 methyltransferase disruptor of telomeric silencing 1-like (DOT1L) is overexpressed in ovarian cancer and that a higher level of DOT1L expression correlates with shorter progression-free and overall survival (OS). Pharmacological inhibition of DOT1L (EPZ-5676, EPZ004777, and SGC0946) or genetic inhibition of DOT1L attenuates the growth of ovarian cancer cells in cell culture and in a mouse xenograft model of ovarian cancer. Transcriptome-wide mRNA expression profiling shows that DOT1L inhibition results in the downregulation of genes involved in cellular biosynthesis pathways and the upregulation of proapoptotic genes. Consistent with the results of transcriptome analysis, the unbiased large-scale metabolomic analysis showed reduced levels of several metabolites of the amino acid and nucleotide biosynthesis pathways after DOT1L inhibition. DOT1L inhibition also resulted in the upregulation of the NKG2D ligand ULBP1 and subsequent increase in natural killer (NK) cell-mediated ovarian cancer eradication. Collectively, our results demonstrate that DOT1L promotes ovarian cancer tumor growth by regulating apoptotic and metabolic pathways as well as NK cell-mediated eradication of ovarian cancer and identifies DOT1L as a new pharmacological target for ovarian cancer therapy.


Sign in / Sign up

Export Citation Format

Share Document